LDS/Medical Tests/Estrogen, Total and Fractionated

Estrogen, Total and Fractionated

Estrogens consist of a group of hormones primarily involved in the female reproductive physiologic functions. Biologically active estrogens include Estrone (E1), Estradiol (E2) and Estriol (E3). Estradiol (E2) is biologically more potent than Estrone (E1) and is primarily produced by ovaries in females and testes in males via aromatization of testosterone. To a lesser extent, adrenal glands and adipose tissue aromatize androstenedione and contribute to circulating E2 in both the sexes. In contrast, E1 is primarily produced by adipose tissue via aromatization of androstenedione. Estriol (E3) is primarily produced by the placenta and hence its levels are significantly higher during pregnancy.

While E1 levels remain somewhat unchanged throughout the life of a female, the levels of E2 are much diminished in pre-pubertal females, significantly high in females of reproductive age group, and decrease after menopause. The levels of estradiol (E2) fluctuate during menstrual cycle, being lowest in the follicular phase and peaking just before ovulation. The levels of E2 increase during the pubertal stages of development in both the sexes. Tanner staging categorizes this development into five stages with Tanner stage I being prepubertal stage and Tanner stage V corresponding to adulthood. Reference values for serum estradiol (E2) needs to be adjusted to the Tanner stage of development (please see reference values section). 

Estrogen is secreted into the bloodstream where most of it (98%) is bound to sex hormone-binding globulin. The unbound free estrogen (2% of total) is the biologically active form. It primarily affects female reproductive organs. The non-reproductive functions of estrogen are many and include collagen metabolism in skin and connective tissue, mineralization of bone, lipid metabolism, regulation of coagulation and platelet adhesion, and cognitive functions of central nervous system. 

Evaluation of serum estradiol (using moderately sensitive assays) serves as an important indicator of female reproductive functions and helps clinical assessment of oligomenorrhea, menopause, infertility and assisted reproductive techniques. Other clinical applications are possible, particularly when highly sensitive assays are employed and they include, but are not limited to, diagnosis of inborn errors of sex steroid metabolism, developmental disorders involving the reproductive system (in both males and females), feminizing disorders of males, therapeutic drug monitoring of estrogen receptor antagonists and estrogen secreting tumors (mostly in males, but also in females).

  • Evaluation of hypogonadism – congenital (Turner’s syndrome, premature ovarian failure) and acquired (autoimmune, trauma, chemotherapy induced, radiation induced)
  • Evaluation of menstrual irregularities – amenorrhea, polycystic ovarian syndrome, ovarian neoplasms, etc.
  • Evaluation of osteoporosis and hormone replacement therapy in postmenopausal women
  • Therapeutic drug monitoring of selective estrogen receptor modifiers (SERM)
  • Evaluation of gynecomastia and other feminizing disorders in men – obesity, liver disease and estrogen secreting tumors
  • Evaluation of disorders of puberty – precocious puberty and delayed puberty
  • Evaluation of menstrual cycle in assisted reproductive procedures including inducing ovulation
The levels of estradiol (E2) may be increased or decreased in various clinical settings. Clinical correlation is necessary at all times. Depending on the indications for testing, correlation with other laboratory tests (serum free testosterone, sex hormone-binding globulin, androstenedione, dihydroepiandrosterone sulfate etc.) and other imaging studies may be necessary.
Adults (pg/mL)
Group Reference Range (pg/mL)
Males 10–40
Females (reproductive age) 15–350
Females (post-menopausal) <10

Children:

  • Neonates: Serum estradiol levels are greatly elevated at birth and fall to baseline prepubertal levels at 3-4 weeks of life.
  • Serum estradiol levels at puberty (for both males and females) vary with the Tanner stage of development and are summarized in the table below:
Tanner Stage (Males) Mean Age (Years) Reference Range (pg/mL)
Stage I (>14 days to prepuberty) 7.1 Undetectable to 13
Stage II 12.1 Undetectable to 16
Stage III 13.6 Undetectable to 26
Stage IV 15.1 Undetectable to 38
Stage V 18 10–40

 

Tanner Stage (Females) Mean Age (Years) Reference Range (pg/mL)
Stage I (>14 days to prepuberty) 7.1 Undetectable to 20
Stage II 10.5 Undetectable to 24
Stage III 11.6 Undetectable to 60
Stage IV 12.3 15–85
Stage V 14.5 15–350*
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) method.

Serum (SST) or Plasma EDTA. 

Stability

  • Ambient: 3-5 days
  • Refrigeration: 5-7 days
  • Frozen: 60 days
Luteinizing Hormone (LH), FSH, Estrogens, Progesterone, Testosterone (Free and Total), Gonadotropin Releasing Hormone (GnRH), HCG Luteinizing Hormone (LH), FSH, Estrogens, Progesterone, Testosterone (Free and Total), Gonadotropin Releasing Hormone (GnRH), HCG, Anti-Mullerian Hormone (AMH).
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • J Midwifery Womens Health. 2002 May-Jun;47(3):130-8. [PMID: 12071379]
  • Pediatr Res. 1973 Nov;7(11):901-7. [PMID: 4795966]
  • Clin Chem Lab Med. 2002 Nov;40(11):1151-60. [PMID: 12521235]
  • Ann Clin Biochem. 1988 Sep;25 ( Pt 5):466-83. [PMID: 3069043]
  • Ann Clin Biochem. 2009 Nov;46(Pt 6):441-56. [PMID: 19841104]
  • Speroff L, Glass RH, Kase NG (editors). Clinical gynecologic endocrinology and infertility. 4th ed. Baltimore:Williams and Wilkins (1989). pp. 91–119.